CIK 0001576885 · <br>Emerging growth company
Acumen Pharmaceuticals, Inc.
Sign in to watch- Ticker
- ABOS
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 364108129
- Phone
- 617-344-4190
- Business address
- 1210-1220 WASHINGTON STREET, SUITE 210, NEWTON, MA, 02465
- 8-K Event Results of operations · Regulation FD disclosure
- 4 Grant or award Director acquired 6,060,606 shares (grant or award)
- SCHEDULE 13D/A Stake Beneficial Ownership Report
- 8-K Event Material agreement · Unregistered share sale · Regulation FD disclosure
- 4 Planned sale Chief Legal Officer & Corp Sec sold 2,090 shares at $3.26 ($6,813)
- 144 Insider Sale of Securities
- 4 Planned sale Chief Legal Officer & Corp Sec sold 9,406 shares at $3.01 ($28,311)
- 144 Insider Sale of Securities
- 4 Planned sale Chief Legal Officer & Corp Sec sold 17,756 shares at an average $3.00 ($53,280)
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- 4 Open-market sale Chief Legal Officer & Corp Sec sold 8,934 shares at an average $1.87 ($16,721)
- 4 Open-market sale Chief Medical Officer sold 3,226 shares at an average $1.81 ($5,833)
- 4 Open-market sale CFO & Chief Business Officer sold 4,160 shares at an average $1.83 ($7,607)
- 4 Open-market sale Chief Executive Officer sold 12,035 shares at an average $1.83 ($21,993)
- 4 Open-market sale Chief Operating Officer sold 2,777 shares at an average $1.81 ($5,031)
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
Page 3 of 19 · 365 filings